Reactive oxygen species, toxicity, oxidative stress, and antioxidants: Chronic diseases and aging

K Jomova, R Raptova, SY Alomar, SH Alwasel… - Archives of …, 2023 - Springer
A physiological level of oxygen/nitrogen free radicals and non-radical reactive species
(collectively known as ROS/RNS) is termed oxidative eustress or “good stress” and is …

Senescence and cancer—role and therapeutic opportunities

CA Schmitt, B Wang, M Demaria - Nature reviews Clinical oncology, 2022 - nature.com
Cellular senescence is a state of stable, terminal cell cycle arrest associated with various
macromolecular changes and a hypersecretory, pro-inflammatory phenotype. Entry of cells …

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

V Subbiah, RJ Kreitman, ZA Wainberg, A Gazzah… - Nature medicine, 2023 - nature.com
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Glioma targeted therapy: insight into future of molecular approaches

K Yang, Z Wu, H Zhang, N Zhang, W Wu, Z Wang… - Molecular Cancer, 2022 - Springer
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Chemistries of bifunctional PROTAC degraders

C Cao, M He, L Wang, Y He, Y Rao - Chemical Society Reviews, 2022 - pubs.rsc.org
Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic
strategy using small molecules to induce ubiquitin-dependent degradation of proteins. It has …

Kinase drug discovery 20 years after imatinib: progress and future directions

P Cohen, D Cross, PA Jänne - Nature reviews drug discovery, 2021 - nature.com
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Signal pathways of melanoma and targeted therapy

W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Advancing targeted protein degradation for cancer therapy

B Dale, M Cheng, KS Park, HÜ Kaniskan… - Nature Reviews …, 2021 - nature.com
The human proteome contains approximately 20,000 proteins, and it is estimated that more
than 600 of them are functionally important for various types of cancers, including nearly 400 …

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

J Tian, JH Chen, SX Chao, K Pelka, M Giannakis… - Nature medicine, 2023 - nature.com
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …

Metastatic colorectal cancer: mechanisms and emerging therapeutics

AE Shin, FG Giancotti, AK Rustgi - Trends in pharmacological sciences, 2023 - cell.com
Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …